Protocol Ledger

NCT06553027 · Phase III · ACTIVE NOT RECRUITING

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

Interventional Phase III clinical trial protocol NCT06553027 sponsored by Cerevance in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-20 Enrollment: 330 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06553027
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)330 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06553027
Protocol FieldVerified Registry Value
NCT IdentifierNCT06553027
Consolidated Lead SponsorCerevance
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment330 participants (ESTIMATED)
Registered Start Date2024-09-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06553027
Hospital Research SiteLocationSite Profile
University of Alabama at BirminghamBirmingham, ALOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI